Medpace Holdings, Inc.
$513.23
▼
-0.32%
2026-04-22 10:12:13
www.medpace.com
NMS: MEDP
Explore Medpace Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$14.67 B
Current Price
$513.23
52W High / Low
$628.92 / $250.05
Stock P/E
33.75
Book Value
$16.18
Dividend Yield
—
ROCE
84.68%
ROE
70.23%
Face Value
—
EPS
—
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
6,200
Beta
1.39
Debt / Equity
29.81
Current Ratio
0.74
Quick Ratio
0.74
Forward P/E
25.67
Price / Sales
5.57
Enterprise Value
$13.65 B
EV / EBITDA
24.24
EV / Revenue
5.39
Rating
Hold
Target Price
$500.08
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Current ratio suggests tighter short-term liquidity.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Twist Bioscience Corporation | $61.88 | — | $3.79 B | — | -24.75% | -16.79% | $62.09 / $23.3 | $7.44 |
| 2. | Mettler-Toledo International Inc. | $1,328.56 | 31.6 | $26.93 B | — | 44.48% | -1154.87% | $1,525.17 / $962.54 | $-1.16 |
| 3. | Personalis, Inc. | $6.34 | — | $663.37 M | — | -29.9% | -35.02% | $11.5 / $3.09 | $2.55 |
| 4. | GeneDx Holdings Corp. | $69.71 | — | $1.92 B | — | -3.15% | -7.6% | $170.87 / $55.17 | $10.54 |
| 5. | Mainz Biomed N.V. | $0.47 | — | $5.89 M | — | -252.7% | -4.88% | $4.43 / $0.4 | $0.62 |
| 6. | GRAIL, Inc. | $51.2 | — | $2.1 B | — | -18.79% | -16.07% | $118.84 / $25.56 | $63.92 |
| 7. | Danaher Corporation | $189.21 | 37.67 | $133.79 B | 0.82% | 6.12% | 7.05% | $242.8 / $180.03 | $74.32 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 708.45 M | 659.9 M | 603.31 M | 558.57 M | 536.59 M |
| Operating Profit | 153.27 M | 141.81 M | 126.33 M | 113.52 M | 125.38 M |
| Net Profit | 135.13 M | 111.14 M | 90.26 M | 114.59 M | 117.02 M |
| EPS in Rs | 4.73 | 3.89 | 3.16 | 4.01 | 4.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.53 B | 2.11 B | 1.89 B | 1.46 B |
| Operating Profit | 534.93 M | 446.87 M | 336.82 M | 278.7 M |
| Net Profit | 451.12 M | 404.39 M | 282.81 M | 245.37 M |
| EPS in Rs | 15.8 | 14.16 | 9.9 | 8.59 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.98 B | 2.1 B | 1.66 B | 1.35 B |
| Total Liabilities | 1.52 B | 1.28 B | 1.1 B | 966.11 M |
| Equity | 459.07 M | 825.54 M | 558.95 M | 386.39 M |
| Current Assets | 989.62 M | 1.03 B | 593.83 M | 333.96 M |
| Current Liabilities | 1.34 B | 1.1 B | 925.13 M | 803.47 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 713.22 M | 608.82 M | 433.37 M | 388.05 M |
| Investing CF | -31.14 M | -28.31 M | -34.63 M | -38.74 M |
| Financing CF | -860.39 M | -154.01 M | -182.64 M | -775.77 M |
| Free CF | 681.87 M | 572.27 M | 396.73 M | 351.17 M |
| Capex | -31.36 M | -36.55 M | -36.65 M | -36.88 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 11.84% | 29.17% | — | — |
| Earnings Growth % | 42.99% | 15.26% | — | — |
| Profit Margin % | 19.17% | 15% | 16.81% | — |
| Operating Margin % | 21.19% | 17.86% | 19.09% | — |
| Gross Margin % | 31.12% | 27.81% | 29.62% | — |
| EBITDA Margin % | 22.58% | 19.26% | 20.62% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.